ArticleAMB Express2026
Huangqi Baihe Granules alleviate chemotherapy-induced intestinal mucositis in Drosophila and mice.
Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Chemotherapy-induced intestinal mucositis (CIM) is a significant dose-limiting adverse effect of cancer treatment. Huangqi Baihe Granules (HQBHG) derived from Dunhuang’s ancient medical texts could alleviate radiation brain injury and hypobaric hypoxia-induced acute lung injury. Here, the protective effect and mechanism of HQBHG against irinotecan (CPT-11)-induced intestinal mucositis were detected by using Drosophila melanogaster and mouse models. Oral administration of HQBHG could significantly ameliorate body injury caused by CPT-11, including increased survival rate, rescued locomotion, altered metabolic capacity, restoration of ovarian morphology in flies, and also alleviated body weight loss and diarrhea in mice. Meanwhile, HQBHG supplementation resumed intestinal length and gastrointestinal acid-based homeostasis, reduced epithelial cell death in CPT-11 treated flies. In CPT-11 treated mice, HQBHG increased the gut length, recovered the architecture of the mucosa, and increased the expressions of tight junction proteins (ZO-1 and occludin ). Mechanism study showed that HQBHG remarkably down-regulated the expression levels of NF-κB signaling, the levels of cytokines IL-1β and TNF-α, and intestinal ROS accumulation; whereas it significantly up-regulated the levels of IL-10, and the expression of the Keap1/Nrf2 signaling in the guts. In addition, integrated analysis of 16S rDNA gene sequencing and untargeted metabolomics revealed that HQBHG reversed CPT-11-induced disordered amino acid metabolism of phenylalanine, tyrosine, tryptophan and glycine, which was closely related to the diversity and abundance of gut microbiota such as Escherichia-Shigella and Clostridium_sensu_stricto. Therefore, HQBHG has the potential to be an effective agent for the treatment of CIM by inhibiting the NF-κB pathway, activating the Nrf2/Keap1 pathway and regulating the amino acid metabolism balance in the gut.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.